← All trials
NCT07064759
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2025
- Primary completion
- Nov 30, 2028
- Completion date
- Feb 28, 2029
- First posted
- Jul 15, 2025
- Last posted
- Oct 20, 2025
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- 4D Molecular TherapeuticsLead sponsor
- 4D Molecular TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.